lymphoma A targeted mutational landscape of angioimmunoblastic T-cell
暂无分享,去创建一个
N. Harris | S. Pileri | J. Teruya-Feldstein | A. Lane | G. Inghirami | R. Ribeiro | S. Rodig | D. Dorfman | K. Stevenson | S. Horwitz | E. Jacobsen | D. Weinstock | S. Ferrero | J. Schatz | M. Lunning | E. Hochberg | O. Weigert | A. Louissaint | Sunhee Kim | P. Paolo | Nadja Kopp | D. Bodegom | D. Toscano | Sudha Bolla
[1] J. Vose,et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Abel,et al. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia , 2013, Leukemia.
[3] G. Wahl,et al. MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.
[4] B. Nathwani,et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Mustjoki,et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. , 2012, Blood.
[6] P. Gaulard,et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. , 2012, Blood.
[7] S. Mustjoki,et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.
[8] W. Chan,et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. , 2012, Blood.
[9] Y. Pekarsky,et al. NOTCH1 mutations in CLL associated with trisomy 12. , 2012, Blood.
[10] Christian Bastard,et al. TET2 and DNMT3A mutations in human T-cell lymphoma. , 2012, The New England journal of medicine.
[11] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[12] P. Opolon,et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.
[13] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[14] Steven J. M. Jones,et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers , 2011, Nature.
[15] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[16] R. Gascoyne,et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. , 2010, Cancer research.
[17] E. Reddy,et al. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. , 2010, Genes & cancer.
[18] Ryan D. Morin,et al. Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.
[19] D. Weisenburger,et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Jan Delabie,et al. Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.
[21] T. Molina,et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. , 1999, Leukemia & lymphoma.
[22] M. Engelhard,et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Ryan D. Morin,et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. , 2012, Blood.
[24] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.